Sanofi Ventures, the corporate venture capital arm of French pharmaceutical company Sanofi (NASDAQ: SNY), has grown its assets under management (AUM) to more than $1.4 billion, underscoring its expanding role in financing early-stage biotech and digital health firms.

Launched in 2012, Sanofi Ventures has already invested over $800 million in startups that align with the pharma’s research priorities: immunology, rare diseases, neurology, and vaccines.

The fund backs companies that are both strategically relevant and financially promising, giving Sanofi access to cutting-edge science while supporting young ventures often underserved by traditional financing.

Its portfolio includes a number of high-profile biotech and digital health companies. Notable investments include ReCode Therapeutics (RNA medicines), Kymera Therapeutics (protein degradation therapies), Click Therapeutics (digital therapeutics), and Ossium Health (cell and tissue-based therapies).

These bets illustrate Sanofi Ventures’ dual focus on breakthrough therapeutics and technology-enabled healthcare.

Read also: Fermelanta Secures ¥2 Billion ($13M) in Series A to Advance Synthetic Biology Production

Corporate venture capital has become a vital source of funding in the life sciences sector, where drug development timelines and capital requirements are uniquely demanding.

Sanofi Ventures now ranks among the larger corporate VCs, alongside peers from Novartis, Pfizer, and Johnson & Johnson, giving it substantial influence in shaping the biotech investment landscape.

The milestone signals Sanofi’s commitment to external innovation and its strategy of blending internal R&D with external partnerships. By backing startups at an early stage, the company both strengthens its pipeline prospects and contributes to the broader biotech ecosystem.